探索骨质保护素在心力衰竭中的临床实用性 - - 一个系统性审查和元分析
Gifar Gazi1, Gabi Gazi1, Robert Cristian Cruciat1
1Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania.
International journal of molecular sciences
|November 27, 2025
概括
与对照组相比,心力衰竭 (HF) 患者的骨质保护素 (OPG) 水平较高. 虽然OPG在NYHA II患者中增加,但对NYHA II/III组需要进一步研究.
科学领域:
- 心脏病学 心脏病学
- 生物化学 生物化学
- 生物标志物 生物标志物
背景情况:
- 骨质保护蛋白 (OPG) 是一种参与骨代谢和心血管健康的糖蛋白.
- 新出现的证据表明OPG在心力衰竭 (HF) 中发挥了作用,但其与HF严重程度的关联尚不清楚.
- 作为HF中的生物标志物,OPG的潜力需要进一步研究.
研究的目的:
- 在心力衰竭 (HF) 患者中系统地审查和元分析循环的骨质保护素 (OPG) 水平.
- 通过纽约心脏协会 (NYHA) 的分类来评估OPG水平和HF严重程度之间的关系.
- 确定OPG是否可以作为HF进展的可靠生物标志物.
主要方法:
- 在PubMed,EMBASE和Scopus进行了全面的文献搜索.
- 包含了报告HF患者和对照组OPG水平的观察性研究.
- 随机效应元分析被用来汇集数据,根据NYHA分类进行子组分析.
主要成果:
- 分析了包括1387名参与者的13项研究.
- 总的来说,与健康对照组相比,HF患者的OPG水平显著增加 (MD 2.490 [95% CI 0.531, 4.449]).
- 亚组分析显示,对照组与NYHA II患者相比,OPG显著降低,但对于NYHA II/III患者组合而言没有显著差异.
结论:
- 在心力衰竭患者中,循环OPG水平显著升高.
- 在NYHA II患者中观察到OPG水平的逐渐增加.
- 需要进行进一步的研究,以澄清OPG在HF严重程度不同阶段的作用,特别是详细的NYHA分类.
更多相关视频
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
5.8K
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.9K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
869
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
869
01:29Heart Failure II: Pathophysiology
658
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
658
01:17Pathophysiology of Heart Failure
2.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.6K
01:30Heart Failure V: Medical Management
195
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
195
01:22Heart Failure Drugs: β-Blockers
724
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
724
01:26Heart Failure III: Clinical Manifestations
430
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
430